RoActemra® (tocilizumab) Dosing for Polyarticular Juvenile Idiopathic Arthritis (pJIA)

This material is provided by Roche Products Limited as a licence requirement for this medicine and forms part of the Risk Management Plan

RoActemra is available in three different dosing vials:

400 mg (20 ml) 200 mg (10 ml) 80 mg (4 ml)

	Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
10 mg/kg	10	22.0	100	5.0	80 mg + 80 mg
	12	26.4	120	6.0	80 mg + 80 mg
	14	30.8	140	7.0	80 mg + 80 mg
	16	35.2	160	8.0	80 mg + 80 mg
	18	39.6	180	9.0	200 mg
	20	44.0	200	10.0	200 mg
	22	48.4	220	11.0	80 mg + 80 mg + 80 mg
	24	52.8	240	12.0	80 mg + 80 mg + 80 mg
	26	57.2	260	13.0	200 mg + 80 mg
	28	61.6	280	14.0	200 mg + 80 mg
8 mg/kg	30	66.0	240	12.0	80 mg + 80 mg + 80 mg
	32	70.4	256	12.8	200 mg + 80 mg
	34	74.8	272	13.6	200 mg + 80 mg
	36	79.2	288	14.4	80 mg + 80 mg + 80 mg + 80 mg
	38	83.6	304	15.2	80 mg + 80 mg + 80 mg + 80 mg
	40	88.0	320	16.0	80 mg + 80 mg + 80 mg + 80 mg
	42	92.4	336	16.8	200 mg + 80 mg + 80 mg
	44	96.8	352	17.6	200 mg + 80 mg + 80 mg
	46	101.2	368	18.4	400 mg
	48	105.6	384	19.2	400 mg
	50	110.0	400	20.0	400 mg
	52	114.4	416	20.8	200 mg + 80 mg + 80 mg + 80 mg
	54	118.8	432	21.6	200 mg + 80 mg + 80 mg + 80 mg
	56	123.2	448	22.4	400 mg + 80 mg
	58	127.6	464	23.2	400 mg + 80 mg
	60	132.0	480	24.0	400 mg + 80 mg
	62	136.4	496	24.8	200 mg + 80 mg + 80 mg + 80 mg + 80 mg
	64	140.8	512	25.6	200 mg + 80 mg + 80 mg + 80 mg + 80 mg
	66	145.2	528	26.4	400 mg + 80 mg + 80 mg
	68	149.6	544	27.2	400 mg + 80 mg + 80 mg
	70	154.0	560	28.0	400 mg + 80 mg + 80 mg
	72	158.4	576	28.8	400 mg + 200 mg
	74	162.8	592	29.6	400 mg + 200 mg
	76	167.2	608	30.4	400 mg + 80 mg + 80 mg + 80 mg
	78	171.6	624	31.2	400 mg + 80 mg + 80 mg + 80 mg
	80	176.0	640	32.0	400 mg + 80 mg + 80 mg + 80 mg
	82	180.4	656	32.8	400 mg + 200 mg + 80 mg
	84	184.8	672	33.6	400 mg + 200 mg + 80 mg
	86	189.2	688	34.4	400 mg + 80 mg + 80 mg + 80 mg + 80 mg
	88	193.6	704	35.2	400 mg + 80 mg + 80 mg + 80 mg + 80 mg
	90	198.0	720	36.0	400 mg + 80 mg + 80 mg + 80 mg + 80 mg
	92	202.4	736	36.8	400 mg + 200 mg + 80 mg + 80 mg
	94	206.8	752	37.6	400 mg + 200 mg + 80 mg + 80 mg
	96	211.2	768	38.4	400 mg + 400 mg
	98	215.6	784	39.2	400 mg + 400 mg
	≥100	≥220.0	800	40.0	400 mg + 400 mg

1. Calculate the appropriate dose

RoActemra dosing should be calculated based on the patient's body weight at each administration. Verify the patient's weight, then locate it on the chart to find the corresponding dose and recommended vial combination.

Dosing in pJIA patients is based on the following formulae:

For patients weighing <30 kg

Patient's weight (kg) x 10 mg/kg = RoActemra dose

For patients weighing ≥30 kg

Patient's weight (kg) x 8 mg/kg = RoActemra dose

A change in dose should only be based on a consistent change in the patient's body weight over time.

2. Choose the vial combination of RoActemra that best matches your patient's needs

RoActemra is available in three different dosing vials:

400 mg (20 ml) 200 mg (10 ml) 80 mg (4 ml)

RoActemra is administered as a 60-minute, IV infusion at 4-week intervals.

Infusion reactions

During the infusion, watch the patient closely for any signs and symptoms of hypersensitivity, including anaphylaxis. If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra permanently discontinued.

Full prescribing information can be found in the RoActemra Summary of Product Characteristics (SmPC) via the electronic Medicines Compendium (eMC) website: www.medicines.org.uk.

If you have any further questions relating to RoActemra please contact Roche Medical Information on 0800 3281629 or email: medinfo.uk@roche.com.

Roche

Suspected adverse reactions associated with the use of RoActemra should be reported to: Medicines Authority Post-licensing Directorate 203. Level 3. Rue D'Argens, Gzira GZR 1368, or at: http://www.medicinesauthority.gov.mt/adrportal. Suspected adverse events should also be reported to Roche by phone on +44 (0)1707 367554, fax on +44 (0)1707 367582 or e-mail at welwyn.uk_dsc@roche.com.

RXUKACTE00009 July 2013